
Researchers often include zzso outcomes zzso in Phase III clinical trials to demonstrate the value of treatment from the patient's zzso These data are collected as zzso repeated measures and are often censored by occurrence of a clinical event that defines a survival zzso zzso zzso models having zzso zzso zzso provide a flexible approach to modeling such multiple outcome types zzso We consider the case of many zeros in the zzso data motivating a mixture model, and demonstrate several approaches to modeling multiple zzso zzso with survival in a cancer clinical zzso These joint models may enhance Phase III analyses and better inform health care decision zzso 

